CN106083810A - 一种多取代硫色满酮衍生物的制备方法 - Google Patents
一种多取代硫色满酮衍生物的制备方法 Download PDFInfo
- Publication number
- CN106083810A CN106083810A CN201610392757.9A CN201610392757A CN106083810A CN 106083810 A CN106083810 A CN 106083810A CN 201610392757 A CN201610392757 A CN 201610392757A CN 106083810 A CN106083810 A CN 106083810A
- Authority
- CN
- China
- Prior art keywords
- thiochromanone
- derivant
- preparation
- polysubstituted
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001597008 Nomeidae Species 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims abstract description 16
- -1 carbonyl diurethane thiocarboxylic acid methyl ester Chemical compound 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 7
- SFCCOHHWKRVDHH-UHFFFAOYSA-N 1-(2-bromophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=CC=C1Br SFCCOHHWKRVDHH-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract description 12
- 238000010189 synthetic method Methods 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 abstract description 5
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 abstract description 4
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000047 product Substances 0.000 abstract description 4
- 208000035126 Facies Diseases 0.000 abstract description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract description 3
- 238000004440 column chromatography Methods 0.000 abstract description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 abstract description 3
- 239000000741 silica gel Substances 0.000 abstract description 3
- 229910002027 silica gel Inorganic materials 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 239000012043 crude product Substances 0.000 abstract description 2
- 239000000706 filtrate Substances 0.000 abstract description 2
- 235000019341 magnesium sulphate Nutrition 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 238000001816 cooling Methods 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 238000001228 spectrum Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- MUTCAPXLKRYEPR-ITWZMISCSA-N methyl (e,3r,5s)-7-[4-bromo-2,3-bis(4-fluorophenyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyhept-6-enoate Chemical compound COC(=O)C[C@H](O)C[C@H](O)\C=C\N1C(C(C)C)=C(Br)C(C=2C=CC(F)=CC=2)=C1C1=CC=C(F)C=C1 MUTCAPXLKRYEPR-ITWZMISCSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229940103494 thiosalicylic acid Drugs 0.000 description 2
- PMNLUUOXGOOLSP-UHFFFAOYSA-M 2-sulfanylpropanoate Chemical compound CC(S)C([O-])=O PMNLUUOXGOOLSP-UHFFFAOYSA-M 0.000 description 1
- PZOGWZMTYNFGQP-UHFFFAOYSA-N 3-methylsulfinyl-2,3-dihydrochromen-4-one Chemical compound C1=CC=C2C(=O)C(S(=O)C)COC2=C1 PZOGWZMTYNFGQP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- PIMNFNXBTGPCIL-UHFFFAOYSA-N CC(c1ccccc1Br)=O Chemical compound CC(c1ccccc1Br)=O PIMNFNXBTGPCIL-UHFFFAOYSA-N 0.000 description 1
- BJGOGAYCISIWBZ-UHFFFAOYSA-N CSC(CC(c1ccccc1)=O)=S Chemical compound CSC(CC(c1ccccc1)=O)=S BJGOGAYCISIWBZ-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- MHBLQZYBQMZPCT-UHFFFAOYSA-N O1CCCC2=CC=CC=C12.[S] Chemical compound O1CCCC2=CC=CC=C12.[S] MHBLQZYBQMZPCT-UHFFFAOYSA-N 0.000 description 1
- UCIREQDURSWYHT-UHFFFAOYSA-N O=C1c2ccccc2SC(CC2OC2c2ccccc2)=C1 Chemical compound O=C1c2ccccc2SC(CC2OC2c2ccccc2)=C1 UCIREQDURSWYHT-UHFFFAOYSA-N 0.000 description 1
- 229910018162 SeO2 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- MWPMMAIPUIMWDE-UHFFFAOYSA-N benzoylsulfinyl(phenyl)methanone Chemical compound C(C1=CC=CC=C1)(=O)S(=O)C(C1=CC=CC=C1)=O MWPMMAIPUIMWDE-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- NRUBUZBAZRTHHX-UHFFFAOYSA-N lithium;propan-2-ylazanide Chemical compound [Li+].CC(C)[NH-] NRUBUZBAZRTHHX-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MHNNAWXXUZQSNM-UHFFFAOYSA-N methylethylethylene Natural products CCC(C)=C MHNNAWXXUZQSNM-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- JUKHVNMXKSHNQY-UHFFFAOYSA-N penta-3,4-dien-2-one Chemical compound CC(=O)C=C=C JUKHVNMXKSHNQY-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了属于有机合成技术领域的一种多取代硫色满酮衍生物的制备方法。所述方法为:向反应器中,加入β‑羰基二硫代羧酸甲酯,取代邻溴苯乙酮,碘化亚铜,邻菲罗啉,叔丁醇钠,加入溶剂甲苯,在氮气保护下加热至反应完毕;体系冷却后,加入稀盐酸调pH为中性,用乙酸乙酯分三次进行萃取,合并有机相,加入硫酸镁干燥,过滤,旋转蒸发仪浓缩滤液得到粗产物,用柱层析硅胶分离得到产品。本发明提供的多取代硫色满酮衍生物的合成方法科学合理,合成方法简单,产品易于纯化等特点。其反应方程式如下:
Description
技术领域
本发明属于有机合成技术领域,具体涉及一种多取代硫色满酮衍生物的制备方法。
背景技术
硫色满酮是苯并吡喃酮的硫代同系物,是具有潜力的候选药物。研究表明该类化合物易于通过真菌的细胞膜、改变真菌细胞的超微结构,进而破坏其细胞膜、细胞壁的结构与功能,引起细胞内容物流出导致真菌死亡,因此许多硫色满酮类化合物表现出抗细菌、抗真菌(J.Het.Chem.1985,22,1593)抗病毒(Bioorg.Med.Chem.2008,16,10319)等活性。而且3-烯基取代的硫色满酮,表现出很好的抗肿瘤和抗癌活性(J.Org.Chem.2005,70,7179)。一些衍生物被用作抗疟疾药物(J.Med.Chem.1978,21,643),具有可逆地抑制人体巨细胞病毒的功能(Bioorg.Med.Chem.Lett.1998,8,3677)。
此外,此类化合物还可作为关键中间体用来合成其它具有生物活性的化合物(Eur.J.Med.Chem.1990,25,455;Bioorg.Med.Chem.Lett.1998,8,3677;J.Med.Chem.1996,39,1975)以及用于光不稳定化合物的保护剂(Chem.Commun.2008,2103;Synlett.2012,367)。
鉴于硫色满酮衍生物具有广泛的用途,研究此类化合物的合成方法具有重要的意义。
硫色满酮衍生物的制备方法有:
1)Chen合成法:戊二烯酮在硫化氢气体中和NCS反应,再经SeO2催化得到硫色满酮类衍生物。
2)Kumar合成法:硫代水杨酸在酰氯的作用下在得S-芳酰基硫代水杨酸,然后经由N-苯基(三苯基亚膦基)乙胺的作用下合成硫色满酮。
3)Kataoka合成法:苯甲醛和苯甲酰亚砜在甲苯和哌啶混合溶剂中回流得到亚硫酰基烯酮,通过甲酸处理脱除苄基进行环化反应得到3-(甲基亚磺酰基)-2,3-二氢-4H-1-苯并吡喃-4-酮,此为一对对映异构体,还需要在甲苯中回流以脱除甲磺酸最终得到硫色满酮。
4)Kerstin合成法:巯基丙酸甲酯和2-甲基丁烯酯经过迈克尔加成生成二酯,进而在酸性环境异丙氨基锂催化下发生皂化、脱羧反应,再进一步和NCS反应得到硫色满酮类衍生物。
5)Larock合成法:使用一氯化碘在-78℃的条件下诱导2-(甲硫基)苯基炔酮环化,得到不同碘取代的硫色满酮。
利用上述方法在实验室中制备硫色满酮衍生物,具有明显的缺点:1)所用试剂酰氯、酸或强碱环境不友好;2)反应需要低温操作,条件苛刻;3)合成步骤繁琐且收率不高。
发明内容
为了克服上述现有技术的不足,本发明提供了一种多取代硫色满酮衍生物的制备方法。
一种多取代硫色满酮衍生物的制备方法,所述多取代硫色满酮衍生物具有式Ⅰ所示的结构:
其中,R1选自氢原子、氟原子;R2选自饱和烷基、芳基、取代芳基,芳基是苯基、噻吩基、呋喃基,取代芳基的取代基是氟原子、氯原子、溴原子、甲基、甲氧基、三氟甲基;其特征在于,向反应器中,加入摩尔比为1:2的β-羰基二硫代羧酸甲酯和取代邻溴苯乙酮,在CuI、邻菲罗啉和t-BuONa作用下,溶剂中加热反应完毕后,加稀盐酸,用乙酸乙酯分三次进行萃取,合并有机相,加入硫酸镁干燥,过滤,旋转蒸发仪浓缩滤液得到粗产物,用柱层析硅胶分离得到产品,其化学过程见反应式II:
所述的β-羰基二硫代羧酸甲酯、CuI、邻菲罗啉和t-BuONa的摩尔比值为1:1:1:4。所述溶剂选自甲苯,反应温度为80℃,反应时间为4h。
本发明的有益效果为:本发明提供的多取代硫色满酮衍生物的合成方法科学合理,可以合成得到具有多种取代基的多取代硫色满酮衍生物;而且还具有合成方法简单,产品易于纯化等特点。
附图说明
图1为实施例1制备的化合物3a的1H NMR图谱;
图2为实施例1制备的化合物3a的13C NMR图谱;
图3为实施例3制备的化合物3c的1H NMR图谱;
图4为实施例3制备的化合物3c的13C NMR图谱;
图5为实施例8制备的化合物3h的1H NMR图谱;
图6为实施例8制备的化合物3h的13C NMR图谱。
具体实施方式
下面结合附图和具体的实施例对本发明进一步详细的说明:
下述实施例中所述试验方法,如无特殊说明,均为常规方法;所述试剂和材料,如无特殊说明,均可从商业途径获得。
下述实施例中所用的溶剂使用前均经过无水无氧处理或者加入活化后的分子筛进行简单处理。
实施例1
1)硫色满酮衍生物3a的制备
向25mL三口烧瓶中加入β-羰基二硫代羧酸甲酯2a(0.5mmol,105mg)、CuI(0.5mmol,95mg)、邻菲罗啉(0.5mmol,90.1mg)和t-BuONa(2.0mmol,192mg)。加入甲苯(1.5mL),在80℃、氮气氛围下预搅拌5分钟,将邻溴苯乙酮1a(1.0mmol,190mg)缓慢滴入体系,5分钟内滴完,继续反应4小时。反应完毕后,冷却至室温,加稀盐酸(1M)调至弱酸性,然后用乙酸乙酯萃取3次,有机相用饱和NaCl洗涤并用无水MgSO4干燥30分钟,用旋转蒸发仪除去溶剂,残留物经柱层析分离(200-300目硅胶)(石油醚/乙酸乙酯=5/1)得到黄色固体硫色满酮衍生物3a,其收率为82%。
谱图解析数据3a:
1H NMR(CDCl3,500MHz)δ:4.31(s,2H),6.94(s,1H),7.49-7.52(m,3H),7.56-7.59(m,2H),7.62(t,J=7.45Hz,1H),8.01(d,J=7.6Hz,2H),8.49(d,J=8.05Hz,1H);13C NMR(CDCl3,125MHz)δ:46.2,126.1,126.9,127.7,128.5,128.9,130.0,130.7,131.5,132.7,134.0,135.6,137.5,147.6,180.2,193.5;HRMS(ESI-TOF):calcd for C17H13O2S[M+H]+:281.0636,found:281.0641.
实施例2
用2b代替实例1中的2a,其它条件同实例1,实验结果见表1。
谱图解析数据3b:
1H NMR(CDCl3,500MHz)δ:4.32(s,2H),6.92(s,1H),7.34-7.37(m,1H),7.44-7.46(m,2H),7.52-7.53(m,1H),7.57-7.60(m,2H),8.45(d,J=8.0Hz,1H);13C NMR(CDCl3,125MHz)δ:50.0,126.2,127.0,127.2,127.7,128.5,129.5,130.7,131.5,132.6,137.5,137.8,146.8,180.3,196.5;HRMS(ESI-TOF):calcd for C17H12O2SCl[M+H]+:315.0247,found:315.0250.
实施例3
用2c代替实例1中的2a,其它条件同实例1,实验结果见表1。
谱图解析数据3c:
1H NMR(CDCl3,500MHz)δ:4.27(s,2H),6.89(s,1H),7.21-7.25(m,2H),7.66(d,J=8.4Hz,2H),7.87(d,J=8.45Hz,2H),8.52(dd,1J=8.85Hz,2J=5.9Hz,1H);13C NMR(CDCl3,125MHz)δ:45.6,45.7,112.1(d,2JC-F=24.48Hz),116.5(d,2J C-F=22.29Hz),127.1,127.4,129.6,129.9,131.7(d,3JC-F=8.98Hz),132.4,134.3,139.5,146.8,164.1(d,1JC-F=256.39Hz),179.3,192.5;HRMS(ESI-TOF):calcd for C17H11O2FSBr[M+H]+:376.9647,found:376.9649.
实施例4
用2d代替实例1中的2a,其它条件同实例1,实验结果见表1。
谱图解析数据3d:
1H NMR(CDCl3,500MHz)δ:4.31(s,2H),6.91(s,1H),7.20-7.26(m,2H),7.52(t,J=7.72Hz,2H),7.64(t,J=7.45Hz,1H),8.01(d,J=7.50Hz,2H),8.51(dd,1J=8.92Hz,2J=5.88Hz,1H);13C NMR(CDCl3,125MHz)δ:46.1,112.0(d,2JC-F=24.60Hz),116.3(d,2JC-F=22.28Hz),127.0,127.5,128.5,128.9,131.7(d,3JC-F=8.39Hz),134.1,135.6,139.7,139.7,147.2,164.0(d,1JC-F=256.19Hz),179.3,193.3;HRMS(ESI-TOF):calcd forC17H12O2SF[M+H]+:299.0542,found:299.0553.
实施例5
用2e代替实例1中的2a,其它条件同实例1,实验结果见表1。
谱图解析数据3e:
1H NMR(CDCl3,500MHz)δ:4.34(s,2H),6.94(s,1H),7.52-7.55(m,1H),7.57-7.62(m,2H),7.78(d,J=8.05Hz,2H),8.12(d,J=8.10Hz,2H),8.50(d,J=8.00Hz,1H)13C NMR(CDCl3,125MHz)δ:46.5,60.4,126.1(d,2JC-F=22.46Hz),127.1,127.8,128.6,128.9,130.4,131.7,137.3,138.2,146.8,171.2,180.3,192.7;HRMS(ESI-TOF):calcd forC18H15O2SF3[M+H]+:351.0667,found:351.0672.
实施例6
用2f代替实例1中的2a,其它条件同实例1,实验结果见表1。
谱图解析数据3f:
1H NMR(CDCl3,500MHz)δ:2.42(s,3H),4.28(s,2H),6.94(s,1H),7.29(d,J=8.05Hz,2H),7.49-7.52(m,1H),7.55-7.58(m,2H),7.91(d,J=8.20Hz,2H),8.49(d,J=7.90Hz,1H);13C NMR(CDCl3,125MHz)δ:21.6,46.1,126.1,126.8,127.6,128.5,128.6,129.5,130.0,130.7,131.4,133.2,137.6,145.0,147.9;HRMS(ESI-TOF):calcd forC18H15O2S[M+H]+:295.0793,found:295.0786.
实施例7
用2g代替实例1中的2a,其它条件同实例1,实验结果见表1。
谱图解析数据3g:
1H NMR(CDCl3,500MHz)δ:2.36(s,3H),2.51(s,3H),4.24(s,2H),6.91(s,1H),7.09-7.11(m,2H),7.49-7.52(m,1H),7.55-7.59(m,2H),7.69(d,J=7.75Hz,1H),8.49(d,J=7.90Hz,1H);13C NMR(CDCl3,125MHz)δ:20.4,20.7,47.6,125.2,125.5,125.7,126.6,127.5,128.5,129.8,130.4,132.0,132.3,136.6,139.0,142.3,147.2,179.3,194.9;HRMS(ESI-TOF):calcd for C19H17O2S[M+H]+:309.0952,found:309.0952.
实施例8
用2h代替实例1中的2a,其它条件同实例1,实验结果见表1。
谱图解析数据3h:
1H NMR(CDCl3,500MHz)δ:4.22(s,2H),6.98(s,1H),7.18(t,J=4.35Hz,1H),7.50-7.53(m,1H),7.73(d,J=4.85Hz,1H),7.84(d,J=3.70Hz,1H),8.49(d,J=8.00Hz,1H);13CNMR(CDCl3,125MHz)δ:47.0,126.2,126.8,127.7,128.5,130.7,131.5,133.2,135.4,137.4,142.7,147.2,180.3,186.1;HRMS(ESI-TOF):calcd for C15H12O2S2[M+H]+:287.0200,found:287.0205.
实施例9
用2i代替实例1中的2a,其它条件同实例1,实验结果见表1。
谱图解析数据3i:
1H NMR(CDCl3,500MHz)δ:2.30(s,3H),3.74(s,2H),6.87(s,1H),7.51-7.62(m,3H),8.50(d,J=7.95Hz,1H);13C NMR(CDCl3,125MHz)δ:29.5,51.2,126.2,126.7,127.8,128.5,130.7,131.6,137.3,146.8,180.3,201.5;HRMS(ESI-TOF):calcd for C12H11O2S[M+H]+:219.0480,found:219.0482.
实施例10
用1b代替实例1中的1a,其它条件同实例1,实验结果见表1。
谱图解析数据3j:
1H NMR(CDCl3,500MHz)δ:4.31(s,2H),6.91(s,1H),7.20-7.26(m,2H),7.52(t,J=7.72Hz,1H),7.64(t,J=7.45Hz,2H),8.01(d,J=7.50Hz,2H),8.51(dd,1J=8.92Hz,2J=5.88Hz,1H);13C NMR(CDCl3,125MHz)δ:46.1,112.0(d,2JC-F=24.60Hz),116.3(d,2JC-F=22.28Hz),127.0,127.5,128.5,128.9,131.7(d,3JC-F=8.39Hz),134.0,135.6,139.6,139.7,147.2,164.0(d,1JC-F=256.19Hz),179.2,193.3;HRMS(ESI-TOF):calcd forC17H12O2FS[M+H]+:299.0542,found:299.0549.
表1
Claims (3)
1.一种多取代硫色满酮衍生物的制备方法,所述多取代硫色满酮衍生物具有式I所示的结构:
其中,R1选自氢原子、氟原子;R2选自饱和烷基、芳基、取代芳基,芳基是苯基、噻吩基、呋喃基,取代芳基的取代基是氟原子、氯原子、溴原子、甲基、甲氧基、三氟甲基;其特征在于,向反应器中,加入摩尔比为1:2的β-羰基二硫代羧酸甲酯和取代邻溴苯乙酮,在CuI、邻菲罗啉和t-BuONa作用下,溶剂中加热反应完毕后得到式I所示的硫色满酮衍生物;该制备方法用以下方程式表示:
2.根据权利要求1所述的制备方法,其特征在于:β-羰基二硫代羧酸甲酯、CuI、邻菲罗啉和t-BuONa的摩尔比值为1:1:1:4。
3.按照权利要求1所述的制备方法,其特征在于:溶剂为甲苯,反应温度为80℃,反应时间4小时。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610392757.9A CN106083810A (zh) | 2016-06-06 | 2016-06-06 | 一种多取代硫色满酮衍生物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610392757.9A CN106083810A (zh) | 2016-06-06 | 2016-06-06 | 一种多取代硫色满酮衍生物的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106083810A true CN106083810A (zh) | 2016-11-09 |
Family
ID=57447295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610392757.9A Pending CN106083810A (zh) | 2016-06-06 | 2016-06-06 | 一种多取代硫色满酮衍生物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106083810A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749280A (zh) * | 2017-01-16 | 2017-05-31 | 河南师范大学 | 5H‑喹唑啉[3,2‑b]噌啉‑7,13‑二酮类化合物及其制备方法 |
CN114380790A (zh) * | 2020-10-22 | 2022-04-22 | 中国科学院大连化学物理研究所 | 一种多取代噻喃衍生物及其合成方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1147514A (zh) * | 1996-06-14 | 1997-04-16 | 沈阳药科大学 | 抗真菌剂——硫色(满)酮系列物 |
CN101519402A (zh) * | 2009-04-13 | 2009-09-02 | 南京工业大学 | 一种硫色酮类化合物及其合成方法和在制备抗真菌药物中的应用 |
-
2016
- 2016-06-06 CN CN201610392757.9A patent/CN106083810A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1147514A (zh) * | 1996-06-14 | 1997-04-16 | 沈阳药科大学 | 抗真菌剂——硫色(满)酮系列物 |
CN101519402A (zh) * | 2009-04-13 | 2009-09-02 | 南京工业大学 | 一种硫色酮类化合物及其合成方法和在制备抗真菌药物中的应用 |
Non-Patent Citations (5)
Title |
---|
LI-RONG WEN等: "Dual Roles of β Oxodithioesters in the Copper-Catalyzed Synthesis of Benzo[e]pyrazolo[1,5 c][1,3]thiazine Derivatives", 《THE JOURNAL OF ORGANIC CHEMISTRY》 * |
PHILLIP J. CHASE MABE等: "Preparation of a Select Tautomer of Various Unsymmetrical 1,3,5-Pentanetriones, (1Z,4Z) -(Aryl)-1,5-dihydroxy-5-phenylpenta-1,4-dien-3-ones, a 4H 1-benzothiopyran-4-one, and a 2 (2-oxoyl)quinolin-4(1H) one", 《IND. ENG. CHEM. RES.》 * |
SATORU KITANI等: "Synthesis and characterization of thiochromone S,S-dioxides as new photolabile protecting groups", 《CHEM. COMMUN.》 * |
T. A. JENIFER VIJAY等: "Transition metal free intramolecular S-arylation: one-pot synthesis of thiochromen-4-ones", 《TETRAHEDRON LETTERS》 * |
李明等: "铜促进硫代色酮类化合物的合成研究", 《有机化学》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749280A (zh) * | 2017-01-16 | 2017-05-31 | 河南师范大学 | 5H‑喹唑啉[3,2‑b]噌啉‑7,13‑二酮类化合物及其制备方法 |
CN106749280B (zh) * | 2017-01-16 | 2018-09-18 | 河南师范大学 | 5H-喹唑啉[3,2-b]噌啉-7,13-二酮类化合物及其制备方法 |
CN114380790A (zh) * | 2020-10-22 | 2022-04-22 | 中国科学院大连化学物理研究所 | 一种多取代噻喃衍生物及其合成方法 |
CN114380790B (zh) * | 2020-10-22 | 2023-03-31 | 中国科学院大连化学物理研究所 | 一种多取代噻喃衍生物及其合成方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104926811B (zh) | 3-氰基咪唑并[1,2-a]吡啶化合物的合成方法及其应用 | |
CN106967003A (zh) | 一种合成1,3‑苯并噁嗪‑4‑酮化合物的方法 | |
Le et al. | Synthesis of a new urea derivative: a dual-functional organocatalyst for Knoevenagel condensation in water | |
CN106083810A (zh) | 一种多取代硫色满酮衍生物的制备方法 | |
Gautam et al. | N-Methylpyridinium tosylate catalyzed green and efficient synthesis of some novel 2, 4-disubstituted thiazoles and 4-thiazolidinones | |
CN101402556B (zh) | 新化合物1-环丙基-2-(2-氟苯基)-2-羟基乙酮及其制备方法和用途 | |
Prasad et al. | Design, Synthesis, Antioxidant, and Anti‐Breast Cancer Activities of Novel Diethyl (alkyl/aryl/heteroarylamino)(4‐(pyridin‐2‐yl) phenyl) methylphosphonates | |
Reddy et al. | Structure–activity relationships of chalcone analogs as potential inhibitors of ADP-and collagen-induced platelet aggregation | |
CN106866707B (zh) | 一种苯并咪唑并[2,1-b]噻唑衍生物的制备方法 | |
CN105949161B (zh) | 一种3-芳巯基黄酮化合物的制备方法 | |
CN105820174B (zh) | 一种多取代噻吩并吲哚衍生物的制备方法 | |
Lin et al. | Structure–activity relationship study of growth inhibitory 2-styrylchromones against carcinoma cells | |
CN105669698A (zh) | 一种多取代噻喃并吲哚衍生物的制备方法 | |
CN106038560B (zh) | 一类含硫穿心莲内酯衍生物在制备治疗前列腺癌药物中的应用 | |
CN110698426B (zh) | 叔丁醇钾高效催化制备1,3-苯并噻唑衍生物的方法 | |
CN103724319A (zh) | 一种苯并噻吩类化合物的制备方法及其净化提纯方法 | |
CN111226956B (zh) | 3,6-二取代咪唑[1,2-b]哒嗪类衍生物在制备抑制植物病原真菌杀菌剂中的应用 | |
CN104327025B (zh) | 一种4-芳基萘内酯类衍生物的制备方法 | |
Kumar et al. | Metal-free [3+ 3] heteroannulation of thioamides with alkynyl NHPI-esters to access 2H-1, 3-thiazin-4 (3H)-ones | |
CN104860864B (zh) | 2‑羰基‑5‑炔基吡咯化合物的合成方法 | |
CN108822058B (zh) | 一种苯并噻嗪类化合物的制备方法 | |
Soni et al. | Reactions of coumarin-3-carboxylate, its crystallographic study and antimicrobial activity | |
Mayer et al. | Synthesis of novel steroid analogues containing nitrile and disulfide moieties via palladium-catalyzed cross-coupling reactions | |
Shan et al. | Design, Synthesis, and Biological Evaluation of Chalcone Derivatives as Novel Anticandidal Agents | |
CN108191737A (zh) | N-(2-甲硫基苯基)异吲哚-1,3-二酮化合物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161109 |
|
WD01 | Invention patent application deemed withdrawn after publication |